Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen B King

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Diabetes Technology & Therapeutics|January 29, 2010
Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patientsAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 12, 2010
How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoringAllen B King
Journal of Diabetes Science and Technology|March 10, 2012
Continuous glucose monitoring-guided insulin dosing in pump-treated patients with type 1 diabetes: a clinical guideAllen B King
Journal of Diabetes Science and Technology|May 15, 2015
Misled by the Morning "Fasting" Plasma GlucoseAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 15, 2009
Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is usedAllen B King
Journal of Diabetes Science and Technology|February 20, 2010
No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoringAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Omitting late-night eating may cause hypoglycemia in "well controlled" basal insulin-treated type 2 diabetesAllen B King, Dawn Clark
Drug, Healthcare and Patient Safety|June 25, 2011
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogsKitty Poon, Allen B King
The American Journal of Medicine|October 6, 2014
Individualizing insulin therapy in the management of type 2 diabetesEtie Moghissi, Allen B King
Diabetes Technology & Therapeutics|June 25, 2002
Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart reviewAllen B King, Dana U Armstrong
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Diabetes Technology & Therapeutics|January 29, 2010
Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patientsAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 12, 2010
How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoringAllen B King
Journal of Diabetes Science and Technology|March 10, 2012
Continuous glucose monitoring-guided insulin dosing in pump-treated patients with type 1 diabetes: a clinical guideAllen B King
Journal of Diabetes Science and Technology|May 15, 2015
Misled by the Morning "Fasting" Plasma GlucoseAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 15, 2009
Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is usedAllen B King
Journal of Diabetes Science and Technology|February 20, 2010
No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoringAllen B King
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Omitting late-night eating may cause hypoglycemia in "well controlled" basal insulin-treated type 2 diabetesAllen B King, Dawn Clark
Drug, Healthcare and Patient Safety|June 25, 2011
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogsKitty Poon, Allen B King
The American Journal of Medicine|October 6, 2014
Individualizing insulin therapy in the management of type 2 diabetesEtie Moghissi, Allen B King
Diabetes Technology & Therapeutics|June 25, 2002
Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart reviewAllen B King, Dana U Armstrong
Pageof 3